

**CONTACT - Media:**

Amsterdam +31 20 721 41 33  
Dublin +353 1 617 4249  
Oslo +47 22 34 19 15

Brussels +32 2 620 15 50  
Lisbon +351 210 600 614  
Paris +33 1 70 48 24 45

**CONTACT - Investor Relations:**

+33 1 70 48 24 17

## **PHERECYDES PHARMA LISTS ON EURONEXT GROWTH PARIS TO ACCELERATE ITS FIGHT AGAINST ANTIBIOTIC-RESISTANT BACTERIA**

**€8 MILLION RAISED – MARKET CAPITALISATION OF €34.9 MILLION**



**Paris – 5 February 2021** – Euronext today congratulates Pherecydes Pharma, the French biotech company specialising in the treatment of bacterial infections, especially those that are complicated and/or resistant to antibiotics, on its listing on Euronext Growth Paris (ticker code: ALPHE).

Pherecydes Pharma was created in 2006. Its headquarters are in Nantes, and its research and development centre is based in Romainville. The company develops treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections that do not respond to antibiotic treatment. According to the World Health Organisation, antibiotic resistance could be responsible for more than 10 million deaths per year by 2050<sup>1</sup>. The capital raised will allow Pherecydes Pharma to conduct further clinical tests and potentially to make the medicines available through temporary authorisations for use (TAU) from the second half of 2021.

Pherecydes Pharma was listed through the admission to trading of the 5,824,253 shares making up its equity, including 1,333,265 new shares issued under a Public Offering<sup>2</sup>, after the full exercise of the extension option.

The admission and issue price was set at €6.00 per share. Market capitalisation was €34.9 million on the day of listing. The offering raised €8 million altogether.

The offering was a resounding success with international institutional and individual investors, and was oversubscribed 4 times, with a total demand of €28.1 million.

Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, said: *“The IPO of Pherecydes Pharma marks a new chapter in the life of the company, and I would like to thank all investors that have contributed to the great success of this operation. Thanks to their support, we are more determined than ever to continue our growth and establish our leadership in the field of phagotherapy.”*

<sup>1</sup> Report by Jim O’Neill, 2016

<sup>2</sup> The Public Offering was made up of a Fixed Price Offer and a Global Placement with institutional investors in France and other countries.

Félicitations



**Camille Leca, Euronext's Chief Operating Officer Listing and Head of Listing in France, rang the bell virtually this morning together with Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, to celebrate the company's Initial Public Offering.**

#### **CONTACTS PHERECYDES PHARMA**

Philippe Rousseau (CFO, Pherecydes Pharma): [investors@pherecydes-pharma.com](mailto:investors@pherecydes-pharma.com)

Nicolas Merigeau (Media Relations, NewCap): [nmerigeau@newcap.fr](mailto:nmerigeau@newcap.fr)

#### **CONTACT EURONEXT**

Aurélie Cohen (Europe/Paris):

+33 1 70 48 24 45

[parispressooffice@euronext.com](mailto:parispressooffice@euronext.com)

#### **About Pherecydes Pharma**

Founded in 2006, Pherecydes Pharma is a biotech company that develops treatments for bacteria-resistant infections, responsible for many serious infections. The company has created an innovative approach, precision phagotherapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a range of phages targeting 3 of the most resistant and dangerous bacteria which alone cause more than two thirds of nosocomial resistant infections: *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*. The concept of precision phagotherapy has already been applied successfully to 22 patients in France, as part of compassionate treatment, under the supervision of the National Agency for the Safety of Medicines (ANSM). Pherecydes Pharma, with headquarters in Nantes, relies on a team of 21 employees, many of whom come from the pharmaceutical industry, biotechnology and academic research.

For more information: [www.pherecydes-pharma.com](http://www.pherecydes-pharma.com)

#### **About Euronext**

Euronext is the leading pan-European market infrastructure, connecting local economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, The Netherlands, Norway and Portugal. With close to 1,500 listed issuers worth €4.5 trillion in market capitalisation as of end December 2020, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates Euronext Growth® and Euronext Access®, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Norway and Portugal.

For the latest news, follow us on Twitter ([twitter.com/euronext](https://twitter.com/euronext)) and LinkedIn ([linkedin.com/euronext](https://linkedin.com/euronext)).

#### **Disclaimer**

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at

[www.euronext.com/terms-use](http://www.euronext.com/terms-use).

© 2021, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at:

<https://www.euronext.com/en/privacy-policy>.

In accordance with the applicable legislation you have rights with regard to the processing of your personal data:

- for more information on your rights, please refer to: [https://www.euronext.com/data\\_subjects\\_rights\\_request\\_information](https://www.euronext.com/data_subjects_rights_request_information),
- to make a request regarding processing of your data or to unsubscribe to this press release service, please use our data subject request form at <https://connect2.euronext.com/form/data-subjects-rights-request> or email our Data Protection Officer at [dpo@euronext.com](mailto:dpo@euronext.com).